S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.42 (+0.90%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.42 (+0.90%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

Spectrum Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SPPI)

$7.82
-0.20 (-2.49 %)
(As of 10/21/2019 04:00 PM ET)
Today's Range
$7.75
Now: $7.82
$8.14
50-Day Range
$6.95
MA: $8.16
$9.71
52-Week Range
$6.22
Now: $7.82
$14.65
Volume60,898 shs
Average Volume814,151 shs
Market Capitalization$882.57 million
P/E RatioN/A
Dividend YieldN/A
Beta2.56
Spectrum Pharmaceuticals, Inc develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkin's lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SPPI
CUSIP84763A10
Phone702-835-6300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$109.33 million
Book Value$2.65 per share

Profitability

Net Income$-120,010,000.00

Miscellaneous

Employees235
Market Cap$882.57 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.


Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) issued its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.36) by $0.13. The biotechnology company earned ($1.25) million during the quarter, compared to the consensus estimate of $0.50 million. The company's revenue for the quarter was down 105.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.21) earnings per share. View Spectrum Pharmaceuticals' Earnings History.

When is Spectrum Pharmaceuticals' next earnings date?

Spectrum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Spectrum Pharmaceuticals.

What price target have analysts set for SPPI?

5 equities research analysts have issued 12 month price objectives for Spectrum Pharmaceuticals' shares. Their predictions range from $18.00 to $40.00. On average, they anticipate Spectrum Pharmaceuticals' stock price to reach $23.40 in the next twelve months. This suggests a possible upside of 199.2% from the stock's current price. View Analyst Price Targets for Spectrum Pharmaceuticals.

What is the consensus analysts' recommendation for Spectrum Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spectrum Pharmaceuticals.

What are Wall Street analysts saying about Spectrum Pharmaceuticals stock?

Here are some recent quotes from research analysts about Spectrum Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Spectrum Pharma is progressing well with its lead pipeline candidate, Rolontis and a regulatory application for the same is expected to be filed soon. An approval will boost the prospects of the company. Development of poziotinib is progressing well, including in a phase II pivotal study in second-line lung cancer. Moreover, the sale of its marketed products is helping Spectrum to focus on and support the development of its pipeline candidates. However, Spectrum faced regulatory setbacks including withdrawal of regulatory application for Rolontis seeking approval for neutropenia in the United States. Additional regulatory/development setbacks, especially related to Rolontis, could affect the stock. Loss estimates  have narrowed ahead of Q3 earnings. The company has a mixed record of earnings surprises in the recent quarters." (10/17/2019)
  • 2. HC Wainwright analysts commented, "Our $40 price target is derived from an NPV of Spectrum’s proprietary pipeline, a sum-of-the-parts analysis based on the P/E value of its current commercial business, plus cash. We assume a 20% discount rate for the NPV of the pipeline and a P/S multiple of 3x. We value the pipeline at $12.19 per share (x3= $36.57), the current commercial business at $1.48 per share and YE18 estimated fully diluted net cash at $1.49 per share." (1/10/2019)

Has Spectrum Pharmaceuticals been receiving favorable news coverage?

News coverage about SPPI stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Spectrum Pharmaceuticals earned a news impact score of 0.8 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Spectrum Pharmaceuticals.

Are investors shorting Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 8,730,000 shares, an increase of 10.2% from the August 30th total of 7,920,000 shares. Based on an average daily volume of 779,700 shares, the days-to-cover ratio is presently 11.2 days. Currently, 9.0% of the shares of the stock are sold short. View Spectrum Pharmaceuticals' Current Options Chain.

Who are some of Spectrum Pharmaceuticals' key competitors?

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the folowing people:
  • Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 61)
  • Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 51)
  • Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 43)
  • Mr. Keith M. McGahan J.D., L.L.M., Sr. VP, Chief Legal Officer & Corp. Sec. (Age 43)
  • Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.08%) and Fox Run Management L.L.C. (0.01%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Dolatrai Vyas, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View Institutional Ownership Trends for Spectrum Pharmaceuticals.

Which institutional investors are buying Spectrum Pharmaceuticals stock?

SPPI stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Fox Run Management L.L.C.. View Insider Buying and Selling for Spectrum Pharmaceuticals.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $7.82.

How big of a company is Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals has a market capitalization of $882.57 million and generates $109.33 million in revenue each year. The biotechnology company earns $-120,010,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Spectrum Pharmaceuticals employs 235 workers across the globe.View Additional Information About Spectrum Pharmaceuticals.

What is Spectrum Pharmaceuticals' official website?

The official website for Spectrum Pharmaceuticals is http://www.sppirx.com/.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]


MarketBeat Community Rating for Spectrum Pharmaceuticals (NASDAQ SPPI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  408 (Vote Outperform)
Underperform Votes:  307 (Vote Underperform)
Total Votes:  715
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel